Cystic Fibrosis Foundation Therapeutics Extends Partnership with Proteostasis Therapeutics To Target Delta F508 Treatment

The Cystic Fibrosis Foundation describes CF as a genetically-acquired chronic disease that impacts the lungs and gastrointestinal tract, causing these body systems to produce abnormally thick, and viscid mucus that has the tendency to consolidate in the lungs and block the secretion of pancreatic enzymes, resulting in malabsorption. Today,…

Your CF Community

Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.